Comparative Pharmacology
Head-to-head clinical analysis: AFREZZA versus SOLIQUA 100 33.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFREZZA versus SOLIQUA 100 33.
AFREZZA vs SOLIQUA 100/33
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhaled human insulin that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin binds to the insulin receptor, activating tyrosine kinase activity leading to downstream metabolic effects.
SOLIQUA 100/33 is a fixed-ratio combination of insulin glargine and lixisenatide. Insulin glargine is a long-acting basal insulin analog that binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that potentiates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying.
Inhaled powder; initial dose: 4 units per inhalation at each meal, titrated based on blood glucose; maximum 48 units per meal. Administer via Afrezza Inhaler.
Subcutaneous injection once daily, initial dose 15 units (insulin glargine equivalent) for patients not previously treated with insulin, with 1 unit per 10g carbohydrate or per 15-30 mg/dL blood glucose elevation.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours for insulin component; clinical context: duration of glucose-lowering effect may extend beyond due to receptor binding.
Lixisenatide: ~3 hours; insulin glargine: ~12-24 hours (depot).
Renal: approximately 60-80% as unchanged drug and metabolites (insulin degradation products). Biliary/fecal: minor, <20%.
Renal: ~30% unchanged; biliary/fecal: ~70% as metabolites.
Category C
Category C
Antidiabetic Agent
Antidiabetic Agent